Stopdiar tab. p / o captivity. 100mg # 24

Release form, composition and packaging

?

Film-coated tablets, yellow, round, biconvex.

1 tab.

nifuroxazide 100 mg

colloidal silicon dioxide - 3 mg, potato starch - 179 mg, gelatin - 11 mg, talc - 6 mg, magnesium stearate - 1 mg.

The composition of the shell: hypromellose - 3.31 mg, titanium dioxide - 0.221 mg, talc - 0.124 mg, macrogol 20,000 - 0.276 mg, quinoline yellow dye - 0.069 mg.

24 pcs.

- blisters (1) - cardboard packs.

pharmachologic effect

Antidiarrheal drug. Nifuroxazide is a nitrofuran derivative that has an antibacterial effect against gastrointestinal gram-positive bacteria Staphylococcus spp. and some gram-negative bacteria - Yersinia spp., Escherichia spp., Citobacter spp., Enterobacter spp., Salmonella spp. Nifuroxazide has no antibacterial effect on the bacteria Proteus vulgaris, Proteus mirabilis, Klebsiella spp. and Pseudomonas aeruginosa. It does not affect the composition of the normal bacterial flora of the digestive tract. The detailed mechanism of action of the drug is unknown. Nifuroxazide presumably inhibits the activity of dehydrogenases and protein synthesis in bacterial cells. Does not cause the emergence of drug-resistant strains, and cross-resistance to other antibacterial drugs was not observed.The effectiveness of the action of nifuroxazide does not depend on the pH existing in the intestinal lumen, or on the sensitivity of microorganisms to antibacterial drugs. The drug is practically not absorbed from the digestive tract, it acts exclusively in the intestinal lumen.

Pharmacokinetics

Nifuroxazide is difficult to dissolve.

After oral administration, it is practically not absorbed from the gastrointestinal tract and does not have a systemic effect.

It is excreted through the intestines.

Indications for use

- acute and chronic diarrhea of ��bacterial origin.

Contraindications for use

- hypersensitivity to nifuroxazide, nitrofuran derivatives or any excipient - children under 7 years of age.

Dosage regimen

Is taken internally.

Adults and children over 7 years old are prescribed 2 tablets.

(200 mg) 4 times / day after 6 hours. The course of treatment is 3 days.

If after this period the symptoms do not disappear, the patient should consult a doctor.

The tablet should be swallowed whole, without chewing, without crushing, with an appropriate amount of water.

Overdose

Until now, data on drug overdose have not been reported.

Side effect

Nifuroxazide is well tolerated side effects were practically not observed.

In the presence of increased individual sensitivity to nifuroxazide in isolated cases, the following adverse reactions are possible.

From the digestive system: abdominal pain, nausea, increased diarrhea.

From the hematopoietic system: granulocytopenia.

On the part of the skin and subcutaneous fat: skin rash (including pustular), nodular pruritus.

Allergic reactions: shortness of breath, swelling of the face, lips, tongue, skin rash, itching.

Drug interactions

During treatment with nifuroxazide, concomitant use of other medicinal products for oral administration should be avoided due to the pronounced adsorption properties of nifuroxazide.

Application during pregnancy and lactation

During pregnancy and lactation (breastfeeding), the drug is used only if the intended benefit to the mother outweighs the potential risk to the fetus and child.

Special instructions During treatment, it is necessary orally or parenterally (depending on the patient's condition) to replenish the loss of fluid.

In case of a hypersensitivity reaction (shortness of breath, swelling of the face, lips, tongue, skin rash, itching), you should immediately stop taking the drug.

Drinking alcohol while on nifuroxazide treatment can cause a disulfiram-like reaction.

Influence on the ability to drive vehicles and mechanisms The drug does not affect sp

Name ENG

STOPDIAR

Clinical and pharmacological group

An antibacterial drug derived from nitrofuran.

Antidiarrheal drug

ATX code

Nifuroxazide

Dosage

100mg

Structure

1 tablet, film-coated, contains: active ingredient: nifuroxazide 100 mg: auxiliary substances: colloidal silicon dioxide (aerosil hydrophilic 200) - 3 mg

potato starch - 179 mg

gelatin - 11 mg

talc - 6 mg

magnesium stearate - 1 mg film shell: hypromellose - 3 mg

titanium dioxide - 0.252 mg

talc - 0.062 mg

polyethylene glycol 20,000 - 0.201 mg

dye quinoline yellow - 0.112 mg

Indications

Acute and chronic diarrhea of ��bacterial origin

acute foodborne toxicoinfections.

Storage conditions and periods

At a temperature not higher than 25 degrees.

Expiration date: 4 years

Contraindications

Increased individual sensitivity to the components of the drug, including other derivatives of 5-nitrofuran

fructose intolerance, glucose-galactose malabsorption syndrome, sucrase-isomaltase deficiency

children under 7 years of age.

INN / Active ingredient

nifuroxazide

Specifications

Category

Diarrhea

Scope of the drug

Gastrointestinal tract

Release form

Tablet

Manufacturer country

Poland

Package quantity, pcs

24

Minimum age from

14 years old

Way of introduction

Through the mouth

Vacation conditions

Without recipe

Brand name

Gedeon richter

The amount of the dosage form in the primary package

24 pcs.

Primary packaging type

Blister

Type of consumer packaging

Pack of cardboard

Pharmaco-therapeutic group

Antimicrobial agent - nitrofuran

Anatomical and therapeutic characteristics

A07AX03 Nifuroxazide

Dosage form

Film-coated tablets

The target audience

Children

Dosage (volume) of the substance in the preparation

100 mg

Expiration date in days

1460

Package weight, g

45

Mode of application

:

Stopdiar is recommended for oral administration.

Adults and children over the age of 14 - 200 mg every 6 hours.

The course of treatment is no more than 3 days.

During the treatment of acute diarrhea with the drug, constant oral or intravenous replenishment of fluid deficiency in the body is mandatory, depending on the general condition of the patient.

Information on technical characteristics, delivery set, country of manufacture